Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
Conor A. Bradley(Queen's University Belfast), Sandra Van Schaeybroeck(Queen's University Belfast), Hajrah Khawaja(Queen's University Belfast), Manuel Salto‐Tellez(Queen's University Belfast), Alberto Bardelli(IFOM), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Pierre Laurent‐Puig(Inserm), Mark Lawler(Queen's University Belfast), Patrick G. Johnston(Queen's University Belfast), Josep Tabernero(Deaconess Hospital)
Cited by 241
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k